CO10 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Psoriatic Arthritis

To compare the efficacy of bimekizumab 160mg and secukinumab 150-mg (SEC150) and 300-mg (SEC300) at 52 weeks (Wk52) for the treatment of psoriatic arthritis (PsA) using matching-adjusted indirect comparisons (MAICs).

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P.J. Mease, R.B. Warren, P. Nash, J.M. Grouin, D. Willems, V. Taieb, J. Eells, I. McInnes Source Type: research